Shares of DexCom Inc. DXCM slid 3.59% to $66.11 Monday, on what proved to be an all-around rough trading session for the ...

SAN DIEGO, April 22, 2025--DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, announced today the return of Dexcom U – its one-of-a-kind Name, Image and Likeness program ...

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that designs, develops, and commercializes ...

DXCM is a #3 (Hold) on the Zacks Rank, with a VGM Score of B. Momentum investors should take note of this Medical stock. DXCM has a Momentum Style Score of A, and shares are up 8% over the past ...

NEW YORK, April 22, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of DexCom, Inc. (NASDAQ: DXCM ) breached their ...

Below is Validea's guru fundamental report for DEXCOM INC (DXCM). Of the 22 guru strategies we follow, DXCM rates highest using our P/B Growth Investor model based on the published strategy of ...

DexCom, Inc. DXCM recently unveiled new data for its upcoming G7 15-day continuous glucose monitoring (CGM) sensor at the Advanced Technologies & Treatments for Diabetes (ATTD) conference 2025.

The number of exchange-traded funds (ETFs)offered in the U.S. is approaching 4,000, with providers adding new funds to the slate each month. A small number of these funds, including massive titans ...

In a report released today, Matt Miksic from Barclays maintained a Hold rating on Dexcom (DXCM – Research Report), with a price target of ...

In a report released today, Ryan Zimmerman from BTIG maintained a Buy rating on Dexcom (DXCM – Research Report), with a price target of $107.00. The company’s shares closed last Friday at $66.14.

The Food and Drug Administration has cleared diabetes-management firm DexCom's new continuous glucose monitoring (CGM) system.